Teva Pharmaceutical Industries Limited (TEVA) earnings
TEVA earnings moved a median of +1.57% by the close. Quarterly and annual TEVA reports and results, each read against the price at its own news timestamp. Back to the TEVA overview →
16 measured TEVA earnings events.
Where these TEVA earnings landedvs 16 measured TEVA earnings reactions
| Middle 50% of TEVA earnings reactions | -0.96% to +2.20% |
|---|---|
| Median reaction (to close) | +1.57% |
| Measured reactions | 16 |
Point-in-time · zero look-ahead
Half of the 16 TEVA earnings events with a measured close landed between -0.96% and +2.20%; 69% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Jun 30 | SEC filing · Form 10-Q | +3.25% | +3.33% | |
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Mar 31 | SEC filing · Form 10-Q | -0.14% | -2.31% | |
| Form 10-K TEVA PHARMACEUTICAL INDU For: Dec 31 | SEC filing · Form 10-K | +0.93% | +1.71% | |
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Sep 30 | SEC filing · Form 10-Q | +1.22% | +1.45% | |
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Jun 30 | SEC filing · Form 10-Q | -1.19% | -8.04% | |
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Mar 31 | SEC filing · Form 10-Q | +1.94% | +3.26% | |
| Form 10-K TEVA PHARMACEUTICAL INDU For: Dec 31 | SEC filing · Form 10-K | +0.23% | +0.23% | |
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Sep 30 | SEC filing · Form 10-Q | -0.68% | -0.74% | |
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Jun 30 | SEC filing · Form 10-Q | -0.01% | +1.68% | |
| Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024 | Press release | -0.24% | +1.82% | |
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Mar 31 | SEC filing · Form 10-Q | -0.22% | +1.85% | |
| Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook | Press release | +6.22% | +8.18% | |
| Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 | Press release | +0.47% | +0.36% | |
| Form 10-K TEVA PHARMACEUTICAL INDU For: Dec 31 | SEC filing · Form 10-K | +0.04% | +3.28% | |
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Sep 30 | SEC filing · Form 10-Q | -0.68% | -1.81% | |
| Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance | Press release | +1.02% | -1.61% |
Keep exploring
More TEVA: analyst actions → · SEC filings → · TEVA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ALDER BIOPHARMACEUTICALS INC (ALDR) | 693 | -0.21% | 45% |
| DIGIRAD (DRAD) | 692 | 0.00% | 39% |
| Tyme Technologies, Inc. (TYME) | 691 | -0.28% | 41% |
| Marinus Pharmaceuticals, Inc. (MRNS) | 687 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.